skip to main content

Investors

Shareholder Information

Major Shareholdings

Major shareholder Number of shares Percentage holding
North West Fund (Biomedical) LP 16,186,446 12.2%
Mercia Fund Managers 15,723,818 11.9%
AXA Framlington 11,848,884 8.9%
Ora Capital 10,000,000 7.5%
Seneca Investment Partners 7,243,097 5.5%
Amati Global 6,666,667 5.0%
Newlands Capital 6,044,815 4.6%
TS Capital 5,078,334 3.8%

There are  132,646,263  ordinary shares in issue, of which 26% is not in public hands
This page was last updated on 24 May 2019

Latest Investor Presentation

A copy of the latest Investor Presentation is available at this link.

Latest AGM Presentation

A copy of the 2019 AGM Presentation is available at this link.

STEM Headline Results

The STEM Headline Results webcast (25 March 2019) can be watched at this link or viewed as a visual-only presentation at this link.

Evgen Investor Symposium 2018: Presentations

Introduction – Dr Stephen Franklin, Evgen Pharma plc
Biotech investment market and Evgen Pharma plc – Vadim Alexandre, Northland Capital
The science behind sulforaphane – Prof Albena Dinkova-Kostova, University of Dundee
The STEM trial in breast cancer – Dr Sacha Howell, Christie Hospital and University of Manchester
The SAS trial in haemorrhagic stroke – Sally Ross,  Evgen Pharma plc

Notice of AGM

A copy of the 2019 AGM notice is available at this link.

Advisers and Registrars

Nominated Adviser and Broker:  finnCap
60 New Broad Street, London, EC2M 1JJ

Solicitors: Pinsent Masons LLP 
Pinsent Masons LLP, 30 Crown Place, London, EC2A 4EN

Auditors: RSM UK Audit LLP
9th Floor, 3 Hardman Street, Manchester, M3 3HF

Reporting Accounts: RSM UK Group LLP
25 Farringdon Street, London, EC4A 4AB

Patent Attorney: HGF Ltd
17-19 Whitworth St West, Manchester, M1 5WG

Financial Public Relations: Buchanan
107 Cheapside, London, EC2V 6DN

Registrars: SLC Registrars (a division of Equiniti)
Elder House, St Georges Business Park, Brooklands Road, Weybridge, Surrey, KT13 0TS